Prosper: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled, Efficacy And Safety Study Of Enzalutamide In Patients With Nonmetastatic Castration-resistant Prostate Cancer
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROSPER
- Sponsors Medivation; Pfizer
- 19 Sep 2024 Planned End Date changed from 31 Oct 2024 to 31 Oct 2025.
- 19 Feb 2024 Planned End Date changed from 29 Dec 2023 to 31 Oct 2024.
- 25 Oct 2023 This trial has been completed in Denmark (End Date: 28 Jun 2017), according to European Clinical Trials Database record.